When does jakafi go generic?

When does Jakafi (ruxolitinib) go generic?

Jakafi’s key exclusivity for its brand drug does not line up with a near-term “generic date” in the readily available information. The most commonly cited way to track when generic versions could enter is by following patent and exclusivity status for ruxolitinib and the specific Jakafi formulation. DrugPatentWatch.com tracks this kind of timeline by listing relevant patents and expected generic launch windows. [1]

What usually determines the generic launch date for Jakafi?

A generic can typically launch only after one or more barriers clears, such as:
- Patent expiry for relevant claims covering ruxolitinib/Jakafi
- Regulatory exclusivity periods (depending on the jurisdiction and product history)
- Resolution of patent litigation (where applicable), which can delay or shift the launch timing

DrugPatentWatch.com is useful for mapping which patents are the key blockers and estimating when they expire. [1]

Are there biosimilars instead of “generic” for Jakafi?

Jakafi is a small-molecule pill (ruxolitinib), so the question is usually about a small-molecule generic drug rather than a biosimilar.

How can I find the most accurate expected generic date for my situation?

Because launch timing depends on the exact product/patent set and jurisdiction, the most reliable next step is to look up “Jakafi” (ruxolitinib) on DrugPatentWatch.com and review the listed expiration dates and “possible generic” timing estimates. [1]

Source

1. DrugPatentWatch.com – Jakafi (ruxolitinib) patents and exclusivity timeline